BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16633061)

  • 21. Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions.
    Smith SL; Watson SG; Ratschiller D; Gugger M; Betticher DC; Heighway J
    Oncogene; 2003 Nov; 22(54):8677-87. PubMed ID: 14647462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
    Song J; Shih IeM; Salani R; Chan DW; Zhang Z
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
    Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
    J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y; Wang J; Xiang D; Wang D; Xin X
    Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maspin expression in oral squamous cell carcinoma.
    Iezzi G; Piattelli A; Rubini C; Goteri G; Artese L; Perrotti V; Carinci F
    J Craniofac Surg; 2007 Sep; 18(5):1039-43. PubMed ID: 17912078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
    Surowiak P; Materna V; Kaplenko I; Spaczynski M; Dolinska-Krajewska B; Gebarowska E; Dietel M; Zabel M; Lage H
    Clin Cancer Res; 2006 Dec; 12(23):7149-58. PubMed ID: 17145840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maspin expression and its clinical significance in non-small cell lung cancer.
    Nakagawa M; Katakura H; Adachi M; Takenaka K; Yanagihara K; Otake Y; Wada H; Tanaka F
    Ann Surg Oncol; 2006 Nov; 13(11):1517-23. PubMed ID: 17009165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RUNX3 protein is overexpressed in human epithelial ovarian cancer.
    Nevadunsky NS; Barbieri JS; Kwong J; Merritt MA; Welch WR; Berkowitz RS; Mok SC
    Gynecol Oncol; 2009 Feb; 112(2):325-30. PubMed ID: 18937968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of maspin in colorectal cancer.
    Umekita Y; Souda M; Yoshida H
    In Vivo; 2006; 20(6B):797-800. PubMed ID: 17203770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity.
    Baba T; Mori S; Matsumura N; Kariya M; Murphy SK; Kondoh E; Kusakari T; Kuroda H; Mandai M; Higuchi T; Takakura K; Fukuda MN; Fujii S
    Biochem Biophys Res Commun; 2007 Aug; 360(2):363-9. PubMed ID: 17597582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
    Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
    Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors.
    Schwarz S; Ettl T; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
    Oral Oncol; 2008 Jun; 44(6):563-70. PubMed ID: 17936671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF).
    Cho JH; Kim HS; Park CS; Kim JK; Jung KY; Shin BK; Kim HK
    Oral Oncol; 2007 Mar; 43(3):272-7. PubMed ID: 17174141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The paradoxical expression of maspin in ovarian carcinoma.
    Sood AK; Fletcher MS; Gruman LM; Coffin JE; Jabbari S; Khalkhali-Ellis Z; Arbour N; Seftor EA; Hendrix MJ
    Clin Cancer Res; 2002 Sep; 8(9):2924-32. PubMed ID: 12231537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
    Hille S; Rein DT; Riffelmann M; Neumann R; Sartorius J; Pfützner A; Kurbacher CM; Schöndorf T; Breidenbach M
    Anticancer Drugs; 2006 Oct; 17(9):1041-4. PubMed ID: 17001177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation of hTERT expression to maspin and bFGF expression and their significance in glioma].
    Wang DL; Wang YF; Shi GS; Huang H
    Ai Zheng; 2007 Jun; 26(6):601-6. PubMed ID: 17562265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
    Chua R; Setzer S; Govindarajan B; Sexton D; Cohen C; Arbiser JL
    J Am Acad Dermatol; 2009 May; 60(5):758-66. PubMed ID: 19389518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nuclear localization of mammary serine protease inhibitor (MASPIN): is its impact on the prognosis in laryngeal carcinoma due to a proapoptotic effect?
    Marioni G; Giacomelli L; D'Alessandro E; Marchese-Ragona R; Staffieri C; Ferraro SM; Staffieri A; Blandamura S
    Am J Otolaryngol; 2008; 29(3):156-62. PubMed ID: 18439947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.